In a very short span, this finding was transformed into an antibody-drug conjugate targeting PTK7 that induced sustained tumor regression, outperformed standard-of-care chemotherapy, and reduced frequency of tumor-initiating cells in a preclinical study45. Here, PTK7 is linked to neoplasm.